Palvella Therapeutics, Inc. (PVLA) Debt Components
- 2025-12-31: Convertible Notes PayableUSD $18.43M; Commercial Paper, at Carrying ValueUSD (m); Debt Instrument, Fair Value DisclosureUSD (m); Debt Instrument, Convertible, Beneficial Conversion FeatureUSD (m).
- 2024-12-31: Convertible Notes PayableUSD $18.43M; Commercial Paper, at Carrying ValueUSD (m); Debt Instrument, Fair Value DisclosureUSD (m); Debt Instrument, Convertible, Beneficial Conversion FeatureUSD (m).
- 2018-12-31: Convertible Notes PayableUSD (m); Commercial Paper, at Carrying ValueUSD $10.91M; Debt Instrument, Fair Value DisclosureUSD (m); Debt Instrument, Convertible, Beneficial Conversion FeatureUSD (m).
- 2017-12-31: Convertible Notes PayableUSD (m); Commercial Paper, at Carrying ValueUSD $13.60M; Debt Instrument, Fair Value DisclosureUSD (m); Debt Instrument, Convertible, Beneficial Conversion FeatureUSD (m).
Palvella Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable USD | Commercial Paper, at Carrying Value USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Convertible, Beneficial Conversion Feature USD |
|---|---|---|---|---|
| 2025-12-31 | $18.43M | (m) | (m) | (m) |
| 2024-12-31 | $18.43M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $10.91M | (m) | (m) |
| 2017-12-31 | (m) | $13.60M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $0.00 | (m) |
| 2017-06-30 | (m) | (m) | $0.00 | (m) |
| 2017-03-31 | (m) | (m) | $0.00 | (m) |
| 2016-12-31 | (m) | (m) | $0.00 | (m) |
| 2016-09-30 | (m) | (m) | $0.00 | (m) |
| 2016-06-30 | (m) | (m) | $0.00 | (m) |
| 2016-03-31 | (m) | (m) | $0.00 | (m) |
| 2015-12-31 | (m) | (m) | $0.00 | (m) |
| 2014-12-31 | (m) | (m) | (m) | 12 month · $2.24M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |